General Information of Drug (ID: DMUFGAY)

Drug Name
Betazole
Synonyms
Ametazole; Betazol; Betazolo; Betazolum; Betazole [INN]; Betazolo [DCIT]; Lilly 96791; Betazol [INN-Spanish]; Betazolum [INN-Latin]; 1H-Pyrazole-3-ethanamine; 2-(1H-Pyrazol-3-yl)ethanamine; 2-(1H-pyrazol-5-yl)ethanamine; 2-(3-Pyrazolyl)ethylamine; 3-(2-Aminoethyl)pyrazole; 3-(beta-aminoethyl)pyrazole
Indication
Disease Entry ICD 11 Status REF
Gastric secretory disorder DD90 Approved [1]
Therapeutic Class
Antihistamines
Affected Organisms
Humans and other mammals
ATC Code
V04CG02: Betazole
V04CG: Tests for gastric secretion
V04C: OTHER DIAGNOSTIC AGENTS
V04: DIAGNOSTIC AGENTS
V: VARIOUS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 111.15
Logarithm of the Partition Coefficient (xlogp) -0.4
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption
The drug is rapidly and completely absorbed []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 4.49852 micromolar/kg/day [2]
Chemical Identifiers
Formula
C5H9N3
IUPAC Name
2-(1H-pyrazol-5-yl)ethanamine
Canonical SMILES
C1=C(NN=C1)CCN
InChI
InChI=1S/C5H9N3/c6-3-1-5-2-4-7-8-5/h2,4H,1,3,6H2,(H,7,8)
InChIKey
JXDFEQONERDKSS-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
7741
ChEBI ID
CHEBI:59170
CAS Number
105-20-4
UNII
1C065P542O
DrugBank ID
DB00272
TTD ID
D01OUE

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H2 receptor (H2R) TTQHJ1K HRH2_HUMAN Antagonist [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7126).
2 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
3 Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin. Am J Gastroenterol. 1988 Jan;83(1):32-6.